tbuckley/cabot-search huggingface dataset:
Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression
Authors: Xin Li, Ye Tian, Mei-Juan Tu, Pui Yan Ho, Neelu Batra, Ai-Ming Yu
Journal: Acta Pharmaceutica Sinica B (2018)

Drug-metabolizing enzymes, transporters, and nuclear receptors are essential for the absorption, distribution, metabolism, and excretion (ADME) of drugs and xenobiotics. MicroRNAs participate in the regulation of ADME gene expression via imperfect complementary Watson-Crick base pairings with target transcripts. We have previously reported that Cytochrome P450 3A4 (CYP3A4) and ATP-binding cassette sub-family G member 2 (ABCG2) are regulated by miR-27b-3p and miR-328-3p, respectively. Here we employed our newly established RNA bioengineering technology to produce bioengineered RNA agents (BERA), namely BERA/miR-27b-3p and BERA/miR-328-3p, via fermentation. When introduced into human cells, BERA/miR-27b-3p and BERA/miR-328-3p were selectively processed to target miRNAs and thus knock down CYP3A4 and ABCG2 mRNA and their protein levels, respectively, as compared to cells treated with vehicle or control RNA. Consequently, BERA/miR-27b-3p led to a lower midazolam 1'-hydroxylase activity, indicating the reduction of CYP3A4 activity. Likewise, BERA/miR-328-3p treatment elevated the intracellular accumulation of anticancer drug mitoxantrone, a classic substrate of ABCG2, hence sensitized the cells to chemotherapy. The results indicate that biologic miRNA agents made by RNA biotechnology may be applied to research on miRNA functions in the regulation of drug metabolism and disposition that could provide insights into the development of more effective therapies.
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
Authors: Johannes Schetelig, Liesbeth C. de Wreede, Michel van Gelder, Linda Koster, Jürgen Finke, Dietger Niederwieser, Dietrich Beelen, G. J. Mufti, Uwe Platzbecker, Arnold Ganser, Silke Heidenreich, Johan Maertens, Gerard Socié, Arne Brecht, Matthias Stelljes, Guido Kobbe, Liisa Volin, Arnon Nagler, Antonin Vitek, Thomas Luft, Per Ljungman, Ibrahim Yakoub-Agha, Marie Robin, Nicolaus Kröger
Journal: Leukemia (2018)

The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.
Increasing Evidence for the Limited Role of Opioids to Treat Chronic Noncancer Pain
Authors: Michael A. Ashburn, Lee A. Fleisher
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Data‐driven adult asthma phenotypes based on clinical characteristics are associated with asthma outcomes twenty years later
Authors: Anne Boudier, Sébastien Chanoine, Simone Accordini, Josep M. Anto, Xavier Basagaña, Jean Bousquet, Pascal Demoly, Judith Garcia‐Aymerich, Frédéric Gormand, Joachim Heinrich, Christer Janson, Nino Künzli, Régis Matran, Christophe Pison, Chantal Raherison, Jordi Sunyer, Raphaëlle Varraso, Deborah Jarvis, Bénédicte Leynaert, Isabelle Pin, Valérie Siroux
Journal: Allergy (2018)

Research based on cluster analyses led to the identification of particular phenotypes confirming phenotypic heterogeneity of asthma. The long-term clinical course of asthma phenotypes defined by clustering analysis remains unknown, although it is a key aspect to underpin their clinical relevance. We aimed to estimate risk of poor asthma events between asthma clusters identified 20 years earlier.The study relied on two cohorts of adults with asthma with 20-year follow-up, ECRHS (European Community Respiratory Health Survey) and EGEA (Epidemiological study on Genetics and Environment of Asthma). Regression models were used to compare asthma characteristics (current asthma, asthma exacerbations, asthma control, quality of life, and FEV1 ) at follow-up and the course of FEV1 between seven cluster-based asthma phenotypes identified 20 years earlier.The analysis included 1325 adults with ever asthma. For each asthma characteristic assessed at follow-up, the risk for adverse outcomes differed significantly between the seven asthma clusters identified at baseline. As compared with the mildest asthma phenotype, ORs (95% CI) for asthma exacerbations varied from 0.9 (0.4 to 2.0) to 4.0 (2.0 to 7.8) and the regression estimates (95% CI) for FEV1 % predicted varied from 0.6 (-3.5 to 4.6) to -9.9 (-14.2 to -5.5) between clusters. Change in FEV1 over time did not differ significantly across clusters.Our findings show that the long-term risk for poor asthma outcomes differed between comprehensive adult asthma phenotypes identified 20 years earlier, and suggest a strong tracking of asthma activity and impaired lung function over time.
Expression of SOX9 and p63: A study of 200 cases to determine their role in human gastric cancer
Authors: Camtu Truong, Wei Feng, Wei Li, Sadir Alrawi, Thaer Khoury, James Yao, Keping Xie, Dongfeng Tan
Journal: Cancer Research (2008)

2197  Background: SOX9, a member of highly mobility group box transcription factor family, has recently been implicated in the development, homeostasis and disease of the gastrointestinal tracts. P63, an isolated p53 homologue, has been used as a marker for metaplastic carcinoma. Expression of SOX9 and p63 have been associated with myoepithelial differentiation of cells. However, the role of SOX2 and p63 in gastric cancer has not been evaluated. The aims of this study were to examine the expression pattern of SOX9 and p63 in human gastric cancer, and to assess their diagnostic value in gastric cancer.  Design: The study consisted of200 consecutive patients with gastric cancer who had received no preoperative treatment. Immunohistochemical analysis was performed using monoclonal antibodies against SOX9 and p63. Unequivocal nuclear staining was recorded as positive, ranging from 1+ to 3+ and depending on the number of positive cells and staining intensity. Normal gastric tissue was used as control. The expression of SOX9 and p63 was analyzed, along with clinicopathologic parameters which included age, sex, as well as location, size, histology, and pathologic stage of the tumor.  Results: SOX9 was readily seen in antral-type glands (1+), and for tumor cases, 66 were negative, and 85, 34, and 15 were 1+, 2+, and 3+ positive for SOX9, respectively. SOX9 tended to be more frequently expressed in well to moderately differentiated carcinoma than in poorly differentiated cancer (p = 0.06). For p63, 191 cases were negative, and 5, 1, and 3 cases were 1+, 2+, and 3+ positive, respectively. Among the nine p63-positive cases, all were sarcomatoid carcinoma. Specifically, p63 was expressed only in the sarcomatoid component of sarcomatoid carcinoma, but not in the adenocarcinoma component (p
Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply
Authors: Valerie Cristina, Murielle Mauer, Anna Dorothea Wagner
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex
Authors: Qianwen Yu, Yue Qiu, Xiaoxiao Chen, Xuhui Wang, Ling Mei, Haiyao Wu, Kai Liu, Yayuan Liu, Man Li, Zhirong Zhang, Qin He
Journal: Theranostics (2018)

Pancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with high lethality. Its high tumor cell-density and large variety of extracellular matrix (ECM) components present major barriers for drug delivery. Methods: Paclitaxel-loaded PEGylated liposomes (PTX-Lip) were used as a tumor-priming agent to induce tumor cell apoptosis and decrease the abundance of ECM to promote cellular uptake and tumor delivery of nanodrugs. Paclitaxel exerts anti-cancer effects but, paradoxically, exacerbates cancer metastasis and drug resistance by increasing the expression of apoptotic B-cell lymphoma-2 protein (BCL-2). Thus, low-molecular-weight heparin-coated lipid-siRNA complex (LH-Lip/siBCL-2) was constructed to inhibit cancer metastasis and silence BCL-2 by BCL-2 siRNA (siBCL-2). Results: Significant tumor growth inhibition efficacy was observed, accompanied by obvious inhibition of cancer metastasis in vivo. Conclusion: These results suggested our sequential delivery of PTX-Lip and LH-Lip/siBCL-2 might provide a practical approach for PDAC or other ECM-rich tumors.
Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
Authors: Clare White, Simon I R Noble, Max Watson, Flavia Swan, Victoria L Allgar, Eoin Napier, Annmarie Nelson, Jayne McAuley, Jennifer Doherty, Bernadette Lee, Miriam J Johnson
Journal: The Lancet Haematology (2019)

The prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs).We did this prospective longitudinal observational study in five SPCUs in England, Wales, and Northern Ireland (four hospices and one palliative care unit). Consecutive adults with cancer underwent bilateral femoral vein ultrasonography on admission and weekly until death or discharge for a maximum of 3 weeks. Data were collected on performance status, attributable symptoms, and variables known to be associated with venous thromboembolism. Patients with a short estimated prognosis (<5 days) were ineligible. The primary endpoint of the study was the prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, analysed by intention to treat. This study is registered with the ISRCTN registry, number ISRCTN97567719.Between June 20, 2016, and Oct 16, 2017, 343 participants were enrolled (mean age 68·2 years [SD 12·8; range 25-102]; 179 [52%] male; mean Australian-modified Karnofsky performance status 49 [SD 16·6; range 20-90]). Of 273 patients with evaluable scans, 92 (34%, 95% CI 28-40) had femoral deep vein thrombosis. Four participants with a scan showing no deep vein thrombosis on admission developed a deep vein thrombosis on repeat scanning over 21 days. Previous venous thromboembolism (p=0·014), being bedbound in the past 12 weeks for any reason (p=0·003), and lower limb oedema (p=0·009) independently predicted deep vein thrombosis. Serum albumin concentration (p=0·43), thromboprophylaxis (p=0·17), and survival (p=0·45) were unrelated to deep vein thrombosis.About a third of patients with advanced cancer admitted to SPCUs had a femoral deep vein thrombosis. Deep vein thrombosis was not associated with thromboprophylaxis, survival, or symptoms other than leg oedema. These findings are consistent with venous thromboembolism being a manifestation of advanced disease rather than a cause of premature death. Thromboprophylaxis for SPCU inpatients with poor performance status seems to be of little benefit.National Institute for Health Research (Research for Patient Benefit programme).
A multifunctional drug nanocarrier for efficient anticancer therapy
Authors: Carmen Teijeiro-Valiño, Ramon Novoa-Carballal, Erea Borrajo, Anxo Vidal, Marta Alonso-Nocelo, María de la Fuente Freire, Pedro P. Lopez-Casas, Manuel Hidalgo, Noémi Csaba, María José Alonso
Journal: Journal of Controlled Release (2018)
The Wide Spectrum of Functional Movement Disorders
Authors: José Fidel Baizabal-Carvallo, Joseph Jankovic
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
PIG-C and SOCS3: Potential immunotargets regulated by non-coding RNAs in TNBC
Authors: M.M. Armanios, R. Abdel Tawab, H.M. El Tayebi
Journal: Annals of Oncology (2018)

Background: Among the crucial proteins having dual role in cancer and immunity is suppressor of cytokine-signaling3 (SOCS3) protein regulating JAK/STAT and IL 6/STAT3/NF-κB pathways, respectively. Another pivotal membrane anchoring protein; PIG-C, that anchors several proteins involved in carcinogenesis. Previous studies proved that miR-34a regulates PDL1. Also, our previous work proved that lncRNAs XIST and TSIX were able to manipulate PDL1 expression in triple negative breast cancer (TNBC). Therefore, this study aims at studying the impact of miR-34a, XIST/TSIX on SOCS3 and PIGC as novel targets to be added to the picture of molecular targeted immunotherapy. Methods: Twenty pairs of BC tissues and adjacent non-BC tissues were collected from patients undergoing tumor resection surgery. MDA-MB-231 cell line was cultured, transfected for manipulation of gene expression purposes. Total RNA was extracted using Biozol followed by reverse transcription cDNA synthesis, amplification and quantification using quantitative-real-time PCR. Results: PIG-C was up-regulated in BC compared to controls (p = 0.0017). MiR-34a decreased PIG-C expression in BC cells lines (p < 0.0001) while anti-miR-34a increased PIG-C (p = 0.0259). MiR-34a increased SOCS3 (p = 0.0192) while anti-miR-34a decreased SOCS-3 (p = 0.0003). Upon XIST knockdown, PIG-C was up-regulated (p = 0.0243) and surprisingly SOCS3 was also up-regulated (p = 0.0092). Oppositely, siTSIX decreased PIG-C (p = 0.0320) and it significantly decreased SOCS3 (p = 0.0005) ensuring the previous results with siXIST. Co-transfection of miR-34a and siXIST decreased PIGC (p < 0.0001). Similarly, PIG-C decreased upon co-transfection of miR-34a and siTSIX (p < 0.0001). SOCS3 increased upon co-transfection of miR-34a with siTSIX (p = 0.0017). Synergistically, SOCS3 increased in the cells co-transfected with miR-34a and siXIST (p = 0.0201). Conclusions: Here, PIG-C and SOCS3 are introduced as new immunotargets in TNBC. In the context of epigenetic regulation, the cross-talk between non-coding RNAs revealed miR-34a to have the lead over XIST and TSIX in regulating PIG-C and SOCS3. These data pave the road for establishing new proteins for molecular targeted immunotherapy along with their key upstream non-coding RNA regulators. Legal entity responsible for the study: German University in Cairo, Egypt. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Synthesis, characterization and in vivo evaluation of honokiol bisphosphate prodrugs protects against rats’ brain ischemia-reperfusion injury
Authors: Gaojie Xu, Renghan Dong, Jin Liu, Li Zhao, Yan Zeng, Xiaofan Xiao, Jinglin An, Sheng Huang, Yueling Zhong, Bing Guang, Tai Yang
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Honokiol (HK) usage is greatly restricted by its poor aqueous solubility and limited oral bioavailability. We synthesized and characterized a novel phosphate prodrug of honokiol (HKP) for in vitro and in vivo use. HKP greatly enhanced the aqueous solubility of HK (127.54 ± 15.53 mg/ml) and the stability in buffer solution was sufficient for intravenous administration. The enzymatic hydrolysis of HKP to HK was extremely rapid in vitro (T1/2= 8.9 ± 2.11 s). Pharmacokinetics studies demonstrated that after intravenous administration of HKP (32 mg/kg), HKP was converted rapidly to HK with a time to reach the maximum plasma concentration of ∼5 min. The prodrug HKP achieved an improved T1/2 (7.97 ± 1.30 h) and terminal volume of distribution (26.02 ± 6.04 ml/kg) compared with direct injection of the equimolar parent drug (0.66 ± 0.01 h) and (2.90 ± 0.342 ml/kg), respectively. Furthermore, oral administration of HKP showed rapid and improved absorption compared with the parent drug. HKP was confirmed to maintain the bioactivity of the parent drug for ameliorating ischemia-reperfusion injury by decreasing brain infarction and improving neurologic function. Taken together, HKP is a potentially useful aqueous-soluble prodrug with improved pharmacokinetic properties which may merit further development as a potential drug candidate.
A Microbiota-Derived Bacteriocin Targets the Host to Confer Diarrhea Resistance in Early-Weaned Piglets
Authors: Jun Hu, Libao Ma, Yangfan Nie, Jianwei Chen, Wenyong Zheng, Xinkai Wang, Chunlin Xie, Zilong Zheng, Zhichang Wang, Tao Yang, Min Shi, Lingli Chen, Qiliang Hou, Yaorong Niu, Xiaofan Xu, Yuhua Zhu, Yong Zhang, Hong Wei, Xianghua Yan
Journal: Cell Host & Microbe (2018)
A confusing “white cell count”: Circulating micromegakaryocytes in post‐thrombocythemia myelofibrosis
Authors: Silvia Sale, Vincenzo Rocco, Ylenia Pancione, Daniele Delli Carri, Maurizio Fumi, Barbara J. Bain
Journal: American Journal of Hematology (2018)

A 55-year-old woman presented to the Emergency Room with rectal bleeding. She had a past medical history of JAK2 V617F-positive essential thrombocythemia transforming to myelofibrosis with hypersplenism; for this, she had had a splenectomy. A blood count on a Siemens ADVIA 2120i showed: white cell count (WBC) 223.8 × 109/L (neutrophils 12.9%, lymphocytes 18.7%, monocytes 4.6%, eosinophils 0.2%, basophils 1.7% and "large unstained cells" [peroxidase-negative cells] 63.6%); hemoglobin concentration 81 g/L; platelet count 494 × 109/L and nucleated red blood cells (NRBCs) 256/100 white cells. In view of the very abnormal blood count and scatter plots (top), microscopic examination was performed. This confirmed the presence of numerous NRBC, these being 75% of the total nucleated cell count (TNCC). However, in addition, there were numerous micromegakaryocytes and apparently bare megakaryocyte nuclei (bottom), constituting 15% of the TNCC. The true WBC was 22.38 × 109/L. Furthermore, microscopy highlighted the presence of numerous platelets including giant platelets; some were hypogranular and some were aggregated. The true platelet count was thus higher than that provided by the analyzer. Micromegakaryocytes are a feature of myelodysplastic syndromes and myeloproliferative/myelodysplastic neoplasms. However, they can also occur during evolution of myeloproliferative neoplasms. In the absence of a spleen, considerable numbers can appear in the peripheral blood and being of similar size to white cells can be counted as such by automated instruments. Nothing to report.
Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study
Authors: Katia B Pagnano, Carmen Fava, Eliana C Miranda, Israel Bendit, Fernanda S Seguro, Gustavo HR Magalhaes, Nelma D Clementino, Monika Conchon, Natália N Gonçalves, Gianluca Gaidano, Monia Lunghi, Arthur Moellmann-Coelho, Ingrid Luise, Micaela Bergamaschi, Dario Ferrero, Renato Centrone, Patrizia Pregno, Laura Fogliatto, Valentina Giai, Matteo Emidio Dragani, Elena Moiraghi, Jaisson Bortolini, Andrea Castelli, Alessandra Cuttica, Teresa Cristina Bortolheiro, Cristiane Pinna, Carmino Antonio De Souza, Giuseppe Saglio
Journal: Blood (2018)
TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates
Authors: Florent Laferrière, Zuzanna Maniecka, Manuela Pérez-Berlanga, Marian Hruska-Plochan, Larissa Gilhespy, Eva-Maria Hock, Ulrich Wagner, Tariq Afroz, Paul J. Boersema, Gery Barmettler, Sandrine C. Foti, Yasmine T. Asi, Adrian M. Isaacs, Ashraf Al-Amoudi, Amanda Lewis, Henning Stahlberg, John Ravits, Francesca De Giorgi, François Ichas, Erwan Bezard, Paola Picotti, Tammaryn Lashley, Magdalini Polymenidou
Journal: Nature Neuroscience (2018)